Perumal, Jai S.

Publications

Sort by

Co-Author Network

selected publications

Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege. The Journal of clinical investigation. 2023 Academic Article GET IT
Times cited: 2
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis. Neurology and therapy. 2023 Academic Article GET IT
Times cited: 24
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study. CNS drugs. 2023 Article GET IT
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS drugs. 2022 Academic Article GET IT
Times cited: 2
Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis. Scientific reports. 2022 Academic Article GET IT
Times cited: 8
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Advances in therapy. 2021 Article GET IT
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Advances in therapy. 2021 Academic Article GET IT
Times cited: 4
A Multi-Ligand Imaging Study Exploring GABAergic Receptor Expression and Inflammation in Multiple Sclerosis. Molecular imaging and biology. 2020 Academic Article GET IT
Times cited: 4
Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2020 Academic Article GET IT
Times cited: 5
Black African and Latino/a identity correlates with increased plasmablasts in MS. Neurology(R) neuroimmunology & neuroinflammation. 2019 Academic Article GET IT
Times cited: 6
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC neurology. 2019 Academic Article GET IT
Times cited: 30
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 164
Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS. Journal of neurology. 2018 Academic Article GET IT
Times cited: 1
Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2017 Letter GET IT
Times cited: 1
Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Multiple sclerosis and related disorders. 2017 Academic Article GET IT
Times cited: 23
Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2017 Academic Article GET IT
Times cited: 9
Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2016 Academic Article GET IT
Times cited: 15
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary clinical trials. 2016 Academic Article GET IT
Times cited: 49
A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatric disease and treatment. 2016 Academic Article GET IT
Times cited: 9
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. Neuropsychiatric disease and treatment. 2015 Review GET IT
Times cited: 7
Disease exacerbation after rituximab induction in neuromyelitis optica. Neurology(R) neuroimmunology & neuroinflammation. 2015 Academic Article GET IT
Times cited: 34
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis. Drug design, development and therapy. 2013 Review GET IT
Times cited: 4
Fingolimod and cardiac risk: latest findings and clinical implications. Therapeutic advances in drug safety. 2013 Academic Article GET IT
Times cited: 18
Emerging disease-modifying therapies in multiple sclerosis. Current treatment options in neurology. 2012 Academic Article GET IT
Times cited: 20
Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. 2012 GET IT
Times cited: 7
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Archives of neurology. 2009 Academic Article GET IT
Times cited: 47
Pediatric-onset multiple sclerosis in African-American black and European-origin white patients. Pediatric neurology. 2009 Academic Article GET IT
Times cited: 32
Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. European journal of neurology. 2008 Academic Article GET IT
Times cited: 72
Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence. Multiple sclerosis (Houndmills, Basingstoke, England). 2008 Academic Article GET IT
Times cited: 9
Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. European journal of neurology. 2008 Academic Article GET IT
Times cited: 47
Acute transverse myelitis with normal brain MRI : long-term risk of MS. Journal of neurology. 2007 Academic Article GET IT
Times cited: 28
Glatiramer acetate therapy for multiple sclerosis: a review. Expert opinion on drug metabolism & toxicology. 2006 Review GET IT
Times cited: 22
Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm. Parkinsonism & related disorders. 2004 Letter GET IT
Times cited: 11

more ...

less ...

Background

education and training

M.B.,B.S., Stanley Medical College, Dr M.G.R Medical University (India) 1997

Contact

full name

Jai S. Perumal

primary email

jsp9007@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Jai S. Perumal Associate Professor of Clinical Neurology

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage